In a 52-week, randomized, controlled, open-label study, 347 children and adolescents with type 1 diabetes were stratified according to age (2 to 5 years, n=82; 6 to 16 years, n=265) at randomization.
- This study evaluated the safety and efficacy of Levemir® and NPH insulin as part of a basal-bolus regimen that included NovoLog® (insulin aspart [rDNA origin] injection) before each meal
- Patients were randomized to receive either Levemir® (n=177) or NPH insulin (n=170) once or twice daily according to their pretrial basal insulin dose regimen
- Patients in the NPH insulin group had no change in FPG (baseline=141 mg/dL)b
- This study had comparable rates of hypoglycemia between Levemir® and NPH insulin